Methylmalonic acid

Selecta Biosciences and AskBio Announce Updates to Methylmalonic Acidemia (MMA-101) Program

Retrieved on: 
Thursday, April 29, 2021
Rare diseases, Methylmalonic acidemia, Methylmalonic acid, Selecta, Mixed martial arts, Health, Clinical medicine

and RESEARCH TRIANGLE PARK, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced an update to the companies\xe2\x80\x99 collaboration to evaluate gene therapy candidate MMA-101 and ImmTOR\xe2\x84\xa2 for the treatment of methylmalonic acidemia (MMA).

Key Points: 
  • and RESEARCH TRIANGLE PARK, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced an update to the companies\xe2\x80\x99 collaboration to evaluate gene therapy candidate MMA-101 and ImmTOR\xe2\x84\xa2 for the treatment of methylmalonic acidemia (MMA).
  • Selecta will assume all rights to the MMA program and will continue to progress the MMA-101 and ImmTOR combination through clinical development.
  • A detailed assessment of the manufacturing process is currently being conducted, and the Company expects to provide an update on program timelines as they are clarified.
  • Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases.

LogicBio Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 9, 2020
Rare diseases, Methylmalonic acidemia, Methylmalonic acid, NASDAQ, Finance, Health, Clinical medicine

- IND for LB-001 in methylmalonic acidemia (MMA) cleared in August 2020, with first patient in Phase 1/2 SUNRISE trial expected to be enrolled in early 2021

Key Points: 
  • - IND for LB-001 in methylmalonic acidemia (MMA) cleared in August 2020, with first patient in Phase 1/2 SUNRISE trial expected to be enrolled in early 2021
    LEXINGTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc.(Nasdaq:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today reported financial results for the quarter endedSeptember 30, 2020 and provided a business update.
  • Following our $48.3 million follow-on public offering in early October, we believe we are well-positioned financially to deliver on our upcoming milestones.
  • LogicBio is developing these highly potent vectors for internal development candidates and potentially for business development collaborations.
  • Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients

Retrieved on: 
Monday, August 10, 2020
Health, Rare diseases, Methylmalonic acidemia, Clinical trial, Methylmalonic acid, Food and Drug Administration

Were pleased to announce our plans for developing LB-001 in pediatric patients with MMA.

Key Points: 
  • Were pleased to announce our plans for developing LB-001 in pediatric patients with MMA.
  • Early intervention in this vulnerable population is critical to combat the manifestation of irreversible clinical disease pathologies including neurological damage.
  • Six leading centers in the United States are expected to participate in the SUNRISE Phase 1/2 trial.
  • LogicBio has received FDA clearance for the first-in-human clinical trial of LB-001, a wholly owned genome editing program leveraging GeneRide for the treatment of methylmalonic acidemia.

Shareholder Alert: Robbins LLP Announces It Is Investigating LogicBio Therapeutics, Inc. (LOGC) for Misleading Shareholders

Retrieved on: 
Wednesday, April 15, 2020
Legal, Professional services, Methylmalonic acidemia, Fiduciary, Methylmalonic acid, Health

Shareholder rights law firm Robbins LLP announces that it is investigating LogicBio Therapeutics, Inc. (NASDAQ: LOGC) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders.

Key Points: 
  • Shareholder rights law firm Robbins LLP announces that it is investigating LogicBio Therapeutics, Inc. (NASDAQ: LOGC) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders.
  • LogicBio is a genome editing company that focuses on developing medicines to treat rare diseases in patients.
  • LogicBio's lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia ("MMA").
  • Then, on January 10, 2020, the Company announced the submission of its IND with the U.S. Food and Drug Administration (FDA).

Shareholder Alert: Robbins LLP Reminds Investors LogicBio Therapeutics, Inc. (LOGC) Sued for Misleading Shareholders

Retrieved on: 
Thursday, April 2, 2020
Legal, Professional services, Rare diseases, Methylmalonic acidemia, Methylmalonic acid, Health, Clinical medicine, Medicine

Shareholder rights law firm Robbins LLP reminds investors that a purchaser of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between December 3, 2018 and February 10, 2020.

Key Points: 
  • Shareholder rights law firm Robbins LLP reminds investors that a purchaser of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between December 3, 2018 and February 10, 2020.
  • LogicBio is a genome editing company that focuses on developing medicines to treat rare diseases in patients.
  • LogicBio's lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia ("MMA").
  • If you suffered a loss as a result of LogicBio's misconduct, click here .

Shareholder Alert: Robbins LLP Announces LogicBio Therapeutics, Inc. (LOGC) Sued for Misleading Shareholders

Retrieved on: 
Friday, March 20, 2020
Legal, Professional services, Rare diseases, Methylmalonic acidemia, Methylmalonic acid, Health, Clinical medicine, Medicine

Shareholder rights law firm Robbins LLP announces that a purchaser of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between December 3, 2018 and February 10, 2020.

Key Points: 
  • Shareholder rights law firm Robbins LLP announces that a purchaser of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between December 3, 2018 and February 10, 2020.
  • LogicBio is a genome editing company that focuses on developing medicines to treat rare diseases in patients.
  • LogicBio's lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia ("MMA").
  • If you suffered a loss as a result of LogicBio's misconduct, click here .

Moderna Announces Open IND for Propionic Acidemia Program (mRNA-3927)

Retrieved on: 
Monday, September 30, 2019
Infectious diseases, FDA, Genetics, Clinical trials, Biotechnology, Pharmaceutical, Health, Rare diseases, Branches of biology, Genetic genealogy, Medical genetics, Propionic acidemia, Methylmalonic acidemia, Propionic acid, Moderna, Acidosis, Methylmalonic acid, Messenger RNA, Isovaleric acidemia, mRNA-3927, Propionic Acidemia, Moderna

We are excited to have a second open IND for a rare disease program and are preparing to move mRNA-3927 into a Phase 1/2 clinical trial in patients with propionic acidemia, said Tal Zaks, M.D., Ph.D., chief medical officer at Moderna.

Key Points: 
  • We are excited to have a second open IND for a rare disease program and are preparing to move mRNA-3927 into a Phase 1/2 clinical trial in patients with propionic acidemia, said Tal Zaks, M.D., Ph.D., chief medical officer at Moderna.
  • There are no approved therapies to treat the underlying cause of propionic acidemia, a rare metabolic disorder that can lead to a toxic buildup of acids in the body.
  • This is the second rare disease candidate from Modernas pipeline with an open IND.
  • The first program, mRNA-3704, is designed to treat methylmalonic acidemia (MMA), another rare metabolic disorder.